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long-term azithromycin therapyTo the Editors
We’ve read with great interest the review of Simoens and
colleagues [1] about the utility of long-term macrolides as a
cost saving strategy in preventing acute exacerbations of
COPD (AECOPD) in Belgium with estimated reductions in the
health annual budget of V355 including the annual hospital
savings and the additional expenditure of the macrolides.
The analysis includes the results of the study conducted by
our group with long-term azithromycin therapy in patients
with severe COPD and repeated AECOPD or chronic colo-
nization by Pseudomonas aeruginosa [2].
We agree with the authors that long-term macrolides
therapy, mainly with azithromycin, in selected severe COPD
patients could be a cost effective strategy with significant
reductions in health budget. Further long-term studies are
needed to define those patients who will benefit from
treatment, with special attention to the development of
macrolide-resistant bacterial strains and the appearance of
long-term side effects. Recently Wenzel and colleagues [3]
have proposed criteria for selecting patients with COPD for
long-term azihromycin prophylaxis based on the results
obtained by Alberts and colleagues [4] in the largest trial
with daily azithromycin (250 mg/day) for one year
demonstrating clinical benefits in some COPD patients with
severe conditions.
In our opinion long-term macrolides should be reserved
to specialized respiratory care units for COPD patients as
respiratory day hospitals (RDH). In our experience a
continued care program for severe COPD in a RDH is able to
reduce AECOPD and hospitalizations compared with COPD
standard care by 40% and 30% respectively [5]. Also RDH
allows a better clinical follow-up and knowledge of each
COPD patient and its previous respiratory status achieving
30% reduction of hospital admissions for AECOPD when the
RDH is compared with conventional emergency de-
partments [6]. We propose long-term azithromycin therapy
(500 mg three days/week) in those severe COPD patients
who despite receiving maximal medical therapy and
continuous clinical care and bacterial monitoring duringhttp://dx.doi.org/10.1016/j.rmed.2013.04.025
0954-6111/ª 2014 Elsevier Ltd. All rights reserved.one year in our RDH persist with a minimum of four mod-
erate to severe AECOPD per year.
In conclusion, the implementation of RDH in pulmonary
departments is a cost effective strategy that can reduce
health budget related to severe COPD management.
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